Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacokinetics of RC28-E in Wet Age-Related Macular Degeneration
NCT03777254Phase 1Completed
- Sponsor
- RemeGen
- Start
- Jan 2019
- Primary completion
- Aug 2019
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label trial of eflimrufusp alfa in exudative macular degeneration (4 arms), sponsored by RemeGen. Primary endpoint: Incidence of ocular and systemic adverse events and serious adverse events at 42 days. Started Jan 2019; status: completed.
02
Drugs
eflimrufusp alfa
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on NCT03777254.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03777254.